Hiroshi Ohtsu Selected Research

candesartan

4/2011	Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
10/2006	Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Ohtsu Research Topics

Disease

12	Inflammation (Inflammations) 10/2017 - 10/2002
11	Hypersensitivity (Allergy) 12/2019 - 06/2002
7	Chronic Renal Insufficiency 10/2023 - 06/2010
7	Hypertension (High Blood Pressure) 11/2021 - 10/2006
7	Anaphylaxis (Anaphylactic Shock) 01/2018 - 08/2002
6	COVID-19 12/2023 - 10/2021
6	Coronary Artery Disease (Coronary Atherosclerosis) 10/2022 - 01/2011
5	Breast Neoplasms (Breast Cancer) 01/2023 - 02/2016
5	Neoplasms (Cancer) 02/2022 - 10/2014
5	Atherosclerosis 04/2011 - 05/2005
4	Heart Failure 01/2022 - 08/2012
4	Hyperplasia 01/2018 - 03/2008
4	Asthma (Bronchial Asthma) 01/2010 - 03/2003
3	Narcolepsy 01/2021 - 12/2013
3	Albuminuria 01/2019 - 06/2010
3	Parkinson Disease (Parkinson's Disease) 01/2019 - 04/2013
3	Proteinuria 12/2018 - 01/2012
3	Tics (Tic) 11/2018 - 01/2014
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 03/2008
3	Cataplexy 10/2016 - 12/2013
3	Ischemia 02/2012 - 03/2010
3	Atrial Fibrillation 04/2011 - 10/2006
3	Eosinophilia 01/2010 - 03/2003
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 04/2009 - 01/2006
3	Contact Dermatitis (Eczema, Contact) 01/2009 - 08/2005
2	Infections 12/2023 - 02/2008
2	Second Primary Neoplasms (Neoplasms, Second) 01/2023 - 03/2020
2	Abdominal Aortic Aneurysm 01/2022 - 01/2016
2	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2022
2	Obesity 11/2021 - 01/2015
2	Pathologic Constriction (Stenosis) 11/2021 - 08/2013
2	Wounds and Injuries (Trauma) 11/2020 - 06/2006
2	Sepsis (Septicemia) 10/2019 - 12/2016
2	Stomach Neoplasms (Stomach Cancer) 01/2018 - 09/2011
2	Dermatitis 01/2017 - 10/2006
2	Pain (Aches) 01/2016 - 09/2013
2	Neuralgia (Stump Neuralgia) 01/2016 - 06/2013
2	Lymphedema (Milroy Disease) 10/2015 - 04/2013
2	Tourette Syndrome (Tourette's Syndrome) 05/2015 - 01/2014
2	Allergic Contact Dermatitis 04/2015 - 09/2012
2	Hypertrophy 08/2012 - 03/2011
2	Ventricular Tachycardia 02/2012 - 03/2006
2	Communicable Diseases (Infectious Diseases) 01/2012 - 01/2010

Drug/Important Bio-Agent (IBA)

51	Histamine (Histamine Dihydrochloride)FDA Link 01/2021 - 06/2002
21	Histidine DecarboxylaseIBA 11/2020 - 08/2002
9	Histamine Receptors (Histamine Receptor)IBA 11/2020 - 01/2006
7	Histamine H1 Receptors (Histamine H1 Receptor)IBA 01/2016 - 10/2002
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 01/2011
5	Histidine (L-Histidine)FDA Link 01/2016 - 03/2003
4	OrexinsIBA 01/2021 - 12/2013
4	AldosteroneIBA 01/2019 - 06/2010
4	NickelIBA 01/2016 - 01/2009
4	Immunoglobulin E (IgE)IBA 11/2015 - 08/2002
4	AntigensIBA 12/2013 - 10/2002
3	pitavastatin (itavastatin)FDA Link 10/2022 - 01/2018
3	Angiotensin Receptor AntagonistsIBA 10/2022 - 04/2011
3	AnticoagulantsIBA 01/2022 - 10/2021
3	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2019 - 06/2010
3	CreatinineIBA 12/2018 - 06/2010
3	Trefoil FactorsIBA 01/2018 - 09/2011
3	InterleukinsIBA 08/2017 - 02/2009
3	CytokinesIBA 12/2016 - 02/2009
3	Mineralocorticoid Receptor AntagonistsIBA 01/2016 - 06/2010
3	CarnosineIBA 02/2015 - 04/2007
3	EnzymesIBA 09/2011 - 08/2002
3	IonsIBA 04/2011 - 01/2009
3	Amlodipine (Norvasc)FDA LinkGeneric 04/2011 - 10/2006
2	Anastrozole (Arimidex)FDA LinkGeneric 01/2023 - 02/2016
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2022 - 12/2014
2	LipidsIBA 10/2022 - 03/2018
2	LDL CholesterolIBA 10/2022 - 01/2018
2	Blood Glucose (Blood Sugar)IBA 04/2022 - 05/2012
2	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2022
2	Trastuzumab (Herceptin)FDA Link 01/2022 - 03/2020
2	Histamine Antagonists (Antihistamines)IBA 01/2021 - 08/2002
2	SaltsIBA 01/2019 - 01/2012
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2017
2	Pepsinogen A (Pepsinogen)IBA 01/2018 - 09/2011
2	Pyrilamine (Mepyramine)FDA Link 01/2016 - 10/2002
2	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2016 - 08/2012
2	CalciumIBA 01/2016 - 10/2006
2	AllergensIBA 11/2015 - 03/2003
2	Histamine H2 ReceptorsIBA 05/2015 - 10/2002
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2015 - 02/2012
2	Eplerenone (Inspra)FDA LinkGeneric 12/2014 - 06/2010
2	AlbuminsIBA 12/2014 - 06/2010
2	Immunoglobulin G (IgG)IBA 09/2011 - 04/2009
2	ApolipoproteinsIBA 04/2011 - 05/2005
2	LipopolysaccharidesIBA 04/2011 - 09/2004
2	candesartanIBA 04/2011 - 10/2006
2	MetalsIBA 04/2011 - 01/2009
2	CholesterolIBA 04/2011 - 05/2005
2	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 04/2011 - 03/2011

Therapy/Procedure

17	Therapeutics 11/2023 - 03/2006
3	Glycemic Control 05/2024 - 05/2012
2	Drug Therapy (Chemotherapy) 02/2022 - 01/2014
2	Adjuvant Chemotherapy 01/2022 - 03/2020
2	Surgical Decompression 11/2021 - 08/2013
2	Ligation 01/2016 - 10/2003
2	Transcranial Magnetic Stimulation 04/2013 - 04/2013